Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
NCT07734415
·
clinicaltrials.gov ↗
PHASE2
Phase
ENROLLING_BY_INVITATION
Status
400
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Atopic Dermatitis Eczema
Eczema
Interventions
DRUG:
IMG-007
Sponsor
Inmagene LLC